merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Safety risks and modest benefit</answer>
<question_number>2</question_number>
<answer>Discourages participation in other trials</answer>
<question_number>3</question_number>
<answer>No correlation</answer>
<question_number>4</question_number>
<answer>Negative perception of safety</answer>
<question_number>5</question_number>
<answer>Discontinuation reduces overall costs</answer>
<question_number>6</question_number>
<answer>Deters participation in other trials</answer>
<question_number>7</question_number>
<answer>Monthly administration and discontinuation</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Intermediate tau levels</answer>